dc.contributor
Institut Català de la Salut
dc.contributor
[Brochet B] INSERM U 1215, University of Bordeaux, Bordeaux, France. [Solari A] Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. [Lechner-Scott J] University of Newcastle, Newcastle, NSW, Australia. Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia. [Piehl F] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. [Langdon D] Department of Psychology, Royal Holloway, University of London, Egham, UK. [Hupperts R] Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center, Maastricht, The Netherlands. [Montalban N] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Hupperts, Raymond
dc.contributor.author
Brochet, Bruno
dc.contributor.author
Solari, Alessandra
dc.contributor.author
Lechner-Scott, Jeannette
dc.contributor.author
Piehl, Fredrik
dc.contributor.author
langdon, dawn
dc.contributor.author
Montalban, Xavier
dc.date.issued
2025-01-15T08:10:21Z
dc.date.issued
2025-01-15T08:10:21Z
dc.identifier
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al. Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. Neurodegener Dis Manag. 2024;14(6):193–201.
dc.identifier
https://hdl.handle.net/11351/12415
dc.identifier
10.1080/17582024.2024.2429970
dc.identifier
001379575600001
dc.description.abstract
Quality of life; Relapsing multiple sclerosis; Tablets
dc.description.abstract
Calidad de vida; Esclerosis múltiple recurrente; Comprimidos
dc.description.abstract
Qualitat de vida; Esclerosi múltiple recurrent; Comprimits
dc.description.abstract
What is this summary about?
This article summarises the findings from the CLARIFY-MS study. Cladribine tablets are an oral medication for the treatment of relapsing multiple sclerosis (MS). The exact number of tablets and number of days depends on the person's body weight. In the CLARIFY-MS study, researchers investigated whether treatment with cladribine tablets improved the health-related quality of life of people with highly active relapsing MS over a 2-year period. Most of the participants(348/482, 72%) were previously treated with other MS diseasemodifying treatments(DMTs) before starting treatment with cladribine tablets in this study.
What were the results?
Treatment with cladribine tablets significantly improved the health-related quality of life of the participants over the 2-year study period. Similar level of improvement in health-related quality of life was seen in participants who had previously been treated with other MS DMTs and in those who had not. Safety findings were also similar to previously reported data for cladribine tablets. No cases of the most severe grade of reduction in lymphocyte counts (grade 4; severely compromised immune system) were recorded.
What do the results mean?
Treatment with cladribine tablets improves the health-related quality of life of people with highly active relapsing MS regardless of whether they received or did not receive DMTs for MS before cladribine tablets treatment.
dc.description.abstract
The CLARIFY-MS study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945).
dc.format
application/pdf
dc.publisher
Taylor & Francis
dc.relation
Neurodegenerative Disease Management;14(6)
dc.relation
https://doi.org/10.1080/17582024.2024.2429970
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pacients - Satisfacció
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
